Retatrutide is a new pharmaceutical in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By activating these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately r